Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Sensipar / Mimpara (cinacalcet by Year
Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Worldwide product sales ($M) ($M)
Amgen Sensipar / Mimpara (cinacalcet: $64M in FY2022, down 23.8% from a year earlier. That is the lowest of the 8 years on record here. No newer figure appears in the documents we track.
Where the FY2022 figure comes from
“|| Sensipar ® /Mimpara ™ | 10 | 54 | 64 | 84 | (24%)”
Source: Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 64 | -23.8% | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 84 | -70.8% | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
| FY2020 | Dec 31, 2020 | 288 | -47.7% | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | 551 | -68.9% | Form 10-K (filed 2020-02-12) ↗ |
| FY2018 | Dec 31, 2018 | 1,774 | +3.3% | Form 10-K (filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 1,718 | +8.6% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 1,582 | +11.8% | Form 10-K (filed 2019-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 1,415 | – | Form 10-K (filed 2018-02-13) ↗ |
Breakdown
What makes up sensipar / Mimpara (cinacalcet
- Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — U.S. product sales ($M)10 · FY2022
- Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Rest of World (ROW) product sales ($M)54 · FY2022
- Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — Worldwide reported sales growth YoY (%)-24.0% · FY2022
Cite this data
StockData. (2026). Amgen Sensipar / Mimpara (cinacalcet ($M), annual FY2015–FY2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-sensipar-ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.